Postmenopausal endometrial pathologies with tamoxifen treatment: Comparison between hysteroscopic and hysterectomy findings

Gynecologic and Obstetric Investigation

Volumn 48, Issue 3, 1999, Pages 187-192

  Cohen, Ilan ^a   Azaria, Ron ^a   Aviram, Rami ^a   Bernheim, Joelle ^a   Tepper, Ron ^a   Cordoba, Mario ^a   Beyth, Yoram ^a  

^a MEIR MEDICAL CENTER   (Israel)

Author keywords

Hysterectomy; Hysteroscopy; Menopause; Tamoxifen

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENDOMETRIUM ATROPHY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN TISSUE; HYSTERECTOMY; HYSTEROSCOPY; MAJOR CLINICAL STUDY; NONHUMAN; POLYP; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYSTERECTOMY; HYSTEROSCOPY; MIDDLE AGED; POLYPS; POSTMENOPAUSE; RISK FACTORS; TAMOXIFEN;

EID: 0032854283     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000010171     Document Type: Article

References (39)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, immune therapy. Lancet 1992;339:1-15.
2. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E: Tamoxifen and the uterus and endometrium. Lancet 1989;ii:375.
3. De Muylder X, Neven P, De Somer M: Endometrial patients undergoing tamoxifen therapy. Int J Gynecol Pathol 1991;36:127-129.
4. Cohen I, Rosen DJD, Shapira J, Cordoba M, Gilboa S, Altaras MM, Beyth Y: Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993;100:567-570.
5. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikinen T: Endometrial changes in potmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-664.
6. Cohen I, Rosen DJD, Shapira J, Cordoba M, Gilboa S, Altaras MM, Beyth Y: Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and non-treated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 1994;52:185-190.
7. Cohen I, Tepper R, Rosen DJD, Shapira J, Cordoba M, Altaras MM, Beyth Y: Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol 1994;55:138-143.
8. Ismail SM: Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994;47:827-833.
9. Kedar RP, Bourne T, Powels TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343: 1318-1321.
10. Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJD, Cordoba M, Beyth Y: Time-dependent effect of tamoxifen therapy on endometrial pathologies in symptomatic, postmenopausal breast cancer patients. Int J Clin Pathol 1996;15:152-157.
11. Gibson LE, Barakat RR, Venkatraman ES: Endometrial pathology at dilatation and curettage in breast cancer patients: Comparison of tamoxifen users and nonusers. Cancer J 1996;2: 35-38.
12. Cohen I, Altaras MM, Shapira J, Tepper R, Cordoba M, Figer A, Beyth Y: Different coexisting endometrial histological features in asymptomatic, postmenopausal breast cancer treated with tamoxifen. Obstet Gynecol Invest 1997;43:60-65.
13. Nouvo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barron B, Winkler B: Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125-131.
14. Corely D, Rowe J, Curtis MJ, Hogan WM, Nuomoff JJ, Livosi VA: Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Gynecol Oncol 1992;79:111-116.
15. Killackey MA, Hakes TB, Pierce VK: Endometrial andenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-238.
16. Ribeiro GM, Swindell R: The Christie Hospital Adjuvant Tamoxifen Trial - Status at 10 years. Br J Cancer 1988;50:601-603.
17. Hardell L: Tamoxifen as a risk factor for carcinoma uteri. Lancet 1988;ii:562.
18. Stewart H, Knight GM: Tamoxifen and the uterus and endometrium. Lancet 1989;i:375-376.
19. Fornander T, Cedermak B, Mattson A, Skoog L, Theve T, Askergen J, Rutquist LE, Glas Y, Silversward C, Somell A, Wilkins N, Hjalmar ML: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;21:117-120.
20. Andersson M, Strom HH, Mouridsen HT: Incidence of new primary cancer after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83: 1013-1017.
21. Segna RA; Dottino PR, Deligdisch L, Cohen CJ: Tamoxifen and endometrial cancer. Mt Sinai J Med 1992;59:416-418.
22. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML: High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-490.
23. Seoud MAF, Johnson J, Weed JC: Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 1993;82:165-169.
24. Fisher B, Costantino JP, Redmond CK, Fisher EB, Wickerham L, Cronin WM: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537.
25. Van Leeuwen FB, Benraadt J, Coebergh JWW, Kiemeney LA, Gimbere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW: Risk of endometrial cancer after tamoxifen treatment for breast cancer. Lancet 1994;343:448-452.
26. Barakat RR, Wang G, Curtin J, Vlamis V, Hoskins WJ: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55:164-168.
27. Rutquist LE, Johnson H, Signomaklo T, Johnson U, Fornander T, Wilking T: Adjuvant tamoxifen therapy for early breast cancer and second primary cancer. J Natl Cancer Inst 1995;87:645-651.
28. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR: Population-based study of tamoxifen and subsequent ovarian, endometrial and breast cancer. J Natl Cancer Inst 1995;87:1359-1364.
29. Robinson DC, Bloss JD, Schiano MA: A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 1995;59:186-190.
30. Cuena RE, Giachino J, Arredondo MH, Hempling R, Edge SB: Endometrial carcinoma associated with breast carcinoma: Low incidence with tamoxifen use. Cancer 1996;77:2058-2063.
31. Sasco AJ, Chaplin G, Amoros E, Saez S: Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy. Epidemiology 1996;7:9-13.
32. Curtis RE, Boice JD, Shiner DA, Hankey BF, Fraumeni JF Jr: Second cancers after adjuvant tamoxifen therapy. J Natl Cancer Inst 1996;88: 832-834.
33. Creasman WT: Endometrial cancer: Incidence, prognostic factors, diagnosis and treatment. Semin Oncol (Suppl) 1997;24:140-150.
34. Stovall TG, Solomon SK, Ling FW: Endometrial sampling prior to hysterectomy. Obstet Gynecol 1989;73:405-409.
35. Ben-Yehuda OM, Kim YB, Leuchter RS: Does hysteroscopy improve upon the sensitivity of dilatation and curettage in the diagnosis of endometrial hyperplasia or carcinoma? Gynecol Oncol 1988;68:4-7.
36. Lossa A, Cianferoni L, Ciatto S, Cecchini S, Campatelli C, Lo Stumbo F: Hysteroscopy and endometrial cancer diagnosis: A review of 2,007 consecutive examinations in self-referral patients. Tumori 1991;77:479-483.
37. Kurman RJ, Norris HJ: Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 1982;49:2547-2559.
38. Kurman RJ, Kaminski PF, Norris HJ: The behavior of endometrial hyperplasia. Cancer 1985;56:403-412.
39. Cohen I, Beyth Y, Tepper R, Figer A, Shapira J, Cordoba M, Altaras MM: Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: A new entity? Gynecol Oncol 1995;58:86-91.